Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor...

Hertfordshire, 07/07/2025 (informazione.news - comunicati stampa - economia)

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. 

Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, including:

The Q-FIX KNOTLESS All-Sutures Anchor offers a versatile range of suture options that include both single-loaded MINITAPE Suture Tape - which has a low profile and coreless design to offer a lower and more evenly distributed level of pressure or ULTRABRAID #2 Suture that is 20% stronger than its nearest competitor.

"When I think of the Q-FIX family I think of reliability,” commented Dr. Robert Litchfield, Orthopedic Surgeon, Sports Medicine Ontario, Canada. “We know that when we put a Q-FIX Anchor in, that we can count on it - the deployment is always predictable and the pullouts are impressive. In my experience, these anchors just don't fail when we put load on them." 

For more information about the Q-FIX KNOTLESS All-Suture Anchor for shoulder repair, please visit here.

For more information about the Q-FIX KNOTLESS All-Suture Anchor for hip repair, please visit here.

- ends –

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

 

*As compared to competitive devices in fixation/pull-out benchtop testing. 

**As compared to the competitive device in cyclic benchtop testing.   

†As compared to competitive all-suture anchors in cyclic and fixation/pull-out benchtop testing. 

‡As demonstrated in benchtop testing; compared to competitive devices.

‡‡ As compared to competitive devices.

 

1. Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975.  
2. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275.  
3. Smith+Nephew 2023. Internal Report. 10090792- Revision B.  
4. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B.  
5. Smith+Nephew 2024. Internal Report. 10144423 Rev B.  
6. ArthroCare 2019. Internal Report. Anchor. P/N 49193-02 Rev B.  
7. Barber FA, et al. Arthroscopy. 2017;33(6):1113-1121. 
8. Nagra NS, et al. Bone Joint Res. 2017;6(2):82-89.  
9. Ruder JA, et al. Arthroscopy. 2019;35(7):1954-1959 e1954.  
10. Smith+Nephew 2023. Internal Report. 10090792 Rev B.  
11. ArthroCare Corporation 2016. Internal Report: P/N 49190-01 Rev.B.  
12. Smith+Nephew 2020. Internal Report. 17-5010-11.  
13. Smith+Nephew 2016.Feasability, MINITAPE Knot Stack Evaluation and Knot Security.15005268. Rev A
14. Smith + Nephew 2013.ULTRATAPE Pressure Film Testing. 15001847. Rev A.
15. Smith+Nephew 2006.USP Knot Strength, ULTRABRAID (white). ITR-2928. Rev E.

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.